S&P 500   3,790.61 (-1.53%)
DOW   30,580.90 (-1.15%)
QQQ   324.32 (-1.30%)
AAPL   143.35 (+0.13%)
MSFT   235.82 (+1.50%)
FB   277.02 (-1.78%)
GOOGL   1,844.72 (-3.31%)
AMZN   3,288.00 (-1.15%)
TSLA   881.44 (-0.19%)
NVDA   522.77 (-2.72%)
BABA   262.94 (-1.12%)
CGC   38.84 (+9.35%)
GE   10.85 (-3.90%)
MU   77.07 (-3.07%)
AMD   91.72 (-3.16%)
NIO   58.28 (-3.37%)
T   29.63 (-0.40%)
F   10.85 (-3.04%)
ACB   11.43 (+7.12%)
BA   195.09 (-3.45%)
DIS   164.78 (-2.82%)
NFLX   539.62 (-3.97%)
GILD   65.89 (-1.21%)
S&P 500   3,790.61 (-1.53%)
DOW   30,580.90 (-1.15%)
QQQ   324.32 (-1.30%)
AAPL   143.35 (+0.13%)
MSFT   235.82 (+1.50%)
FB   277.02 (-1.78%)
GOOGL   1,844.72 (-3.31%)
AMZN   3,288.00 (-1.15%)
TSLA   881.44 (-0.19%)
NVDA   522.77 (-2.72%)
BABA   262.94 (-1.12%)
CGC   38.84 (+9.35%)
GE   10.85 (-3.90%)
MU   77.07 (-3.07%)
AMD   91.72 (-3.16%)
NIO   58.28 (-3.37%)
T   29.63 (-0.40%)
F   10.85 (-3.04%)
ACB   11.43 (+7.12%)
BA   195.09 (-3.45%)
DIS   164.78 (-2.82%)
NFLX   539.62 (-3.97%)
GILD   65.89 (-1.21%)
S&P 500   3,790.61 (-1.53%)
DOW   30,580.90 (-1.15%)
QQQ   324.32 (-1.30%)
AAPL   143.35 (+0.13%)
MSFT   235.82 (+1.50%)
FB   277.02 (-1.78%)
GOOGL   1,844.72 (-3.31%)
AMZN   3,288.00 (-1.15%)
TSLA   881.44 (-0.19%)
NVDA   522.77 (-2.72%)
BABA   262.94 (-1.12%)
CGC   38.84 (+9.35%)
GE   10.85 (-3.90%)
MU   77.07 (-3.07%)
AMD   91.72 (-3.16%)
NIO   58.28 (-3.37%)
T   29.63 (-0.40%)
F   10.85 (-3.04%)
ACB   11.43 (+7.12%)
BA   195.09 (-3.45%)
DIS   164.78 (-2.82%)
NFLX   539.62 (-3.97%)
GILD   65.89 (-1.21%)
S&P 500   3,790.61 (-1.53%)
DOW   30,580.90 (-1.15%)
QQQ   324.32 (-1.30%)
AAPL   143.35 (+0.13%)
MSFT   235.82 (+1.50%)
FB   277.02 (-1.78%)
GOOGL   1,844.72 (-3.31%)
AMZN   3,288.00 (-1.15%)
TSLA   881.44 (-0.19%)
NVDA   522.77 (-2.72%)
BABA   262.94 (-1.12%)
CGC   38.84 (+9.35%)
GE   10.85 (-3.90%)
MU   77.07 (-3.07%)
AMD   91.72 (-3.16%)
NIO   58.28 (-3.37%)
T   29.63 (-0.40%)
F   10.85 (-3.04%)
ACB   11.43 (+7.12%)
BA   195.09 (-3.45%)
DIS   164.78 (-2.82%)
NFLX   539.62 (-3.97%)
GILD   65.89 (-1.21%)
Log in
OTCMKTS:CURLF

Curaleaf Stock Forecast, Price & News

$14.65
-0.24 (-1.61 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$14.24
Now: $14.65
$15.00
50-Day Range
$11.68
MA: $13.33
$16.06
52-Week Range
$2.54
Now: $14.65
$16.69
Volume1.18 million shs
Average Volume1.86 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Curaleaf Holdings, Inc. operates as an integrated medical and wellness cannabis operator in the United States. It operates in two segments, Cannabis Operations and Non-Cannabis Operations. The Cannabis Operations segment engages in the production and sale of cannabis through retail and wholesale channels. The Non-Cannabis Operations segment provides professional services, including cultivation, processing, and retail know-how and back office administration, intellectual property licensing, real estate leasing services, and lending facilities to medical and adult-use cannabis licensees under management service agreements. It offers oils for vaporizing, cartridges, concentrates, tinctures, mints, capsules, edibles, and flower pods. The company also provides hemp-based CBD products. As of June 29, 2020, it operated 57 dispensaries, 15 cultivation sites, and 24 processing sites in 18 states. The company was founded in 2010 and is headquartered in Wakefield, Massachusetts.
Curaleaf logo

MarketRank

Overall MarketRank

1.62 out of 5 stars

Medical Sector

282nd out of 1,925 stocks

Drug Manufacturers - Specialty & Generic Industry

2nd out of 61 stocks

Analyst Opinion: 4.5Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CURLF
CUSIPN/A
CIKN/A
Phone781-451-0150
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Next Earnings DateN/A
OptionableNot Optionable
$14.65
-0.24 (-1.61 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CURLF News and Ratings via Email

Sign-up to receive the latest news and ratings for CURLF and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Curaleaf (OTCMKTS:CURLF) Frequently Asked Questions

How has Curaleaf's stock been impacted by COVID-19 (Coronavirus)?

Curaleaf's stock was trading at $4.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CURLF stock has increased by 231.5% and is now trading at $14.6538.
View which stocks have been most impacted by COVID-19
.

Is Curaleaf a buy right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Curaleaf in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Curaleaf stock.
View analyst ratings for Curaleaf
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Curaleaf?

Wall Street analysts have given Curaleaf a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Curaleaf wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Curaleaf's earnings last quarter?

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) posted its quarterly earnings data on Monday, November, 16th. The company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.02) by $0.01.
View Curaleaf's earnings history
.

What price target have analysts set for CURLF?

7 equities research analysts have issued twelve-month target prices for Curaleaf's shares. Their forecasts range from $16.00 to $29.00. On average, they anticipate Curaleaf's stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 43.3% from the stock's current price.
View analysts' price targets for Curaleaf
or view Wall Street analyst' top-rated stocks.

Are investors shorting Curaleaf?

Curaleaf saw a decline in short interest during the month of December. As of December 31st, there was short interest totaling 869,700 shares, a decline of 40.9% from the December 15th total of 1,472,300 shares. Based on an average daily volume of 1,881,300 shares, the days-to-cover ratio is presently 0.5 days.
View Curaleaf's Short Interest
.

Who are some of Curaleaf's key competitors?

Who are Curaleaf's key executives?

Curaleaf's management team includes the following people:
  • Mr. Boris Alexis Jordan, Exec. Chairman (Age 54, Pay $750k)
  • Mr. Joseph F. Lusardi, CEO & Director (Age 46, Pay $1.01M)
  • Mr. Neil P. Davidson CPA, COO & Treasurer (Age 48, Pay $538.5k)
  • Mr. Joseph Daniel Bayern, Pres (Age 57)
  • Mr. Michael J. Carlotti, Chief Financial Officer (Age 49)
  • Mr. Daniel P. Foley, VP of Fin. & Investor Relations
  • Mr. Peter Clateman, Exec. VP of Bus. Devel. & Acting Gen. Counsel (Age 52)
  • Mr. James S. Shorris, Chief Compliance Officer (Age 59)
  • Ms. Tracy Brady, VP of Corp. Communications
  • Mr. Jason White, Chief Marketing Officer (Age 43)

What is Curaleaf's stock symbol?

Curaleaf trades on the OTCMKTS under the ticker symbol "CURLF."

How do I buy shares of Curaleaf?

Shares of CURLF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Curaleaf's stock price today?

One share of CURLF stock can currently be purchased for approximately $14.65.

What is Curaleaf's official website?

The official website for Curaleaf is www.curaleaf.com.

How can I contact Curaleaf?

The company can be reached via phone at 781-451-0150.

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.